Exawizards Inc. is aiming to receive approval for its AI-powered dementia diagnostic application by the end of fiscal year 2026. The company has initiated consultations with the Pharmaceuticals and Medical Devices Agency (PMDA) regarding the app's development and regulatory pathway. This initiative represents a significant step towards leveraging AI in the early detection and management of Alzheimer's disease. AI
IMPACT This AI application could accelerate dementia diagnosis and improve patient outcomes.
RANK_REASON Company seeking regulatory approval for an AI application.
Read on Mastodon — mastodon.social →
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
